TQ-B3139

DRUG4 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

ALK-positive NSCLCAdvanced CancerNon Small Cell Lung Cancer

Phase 1

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Cancer

Start: 2017-07-19End: 2018-12-31Target: 20Updated: 2017-09-18

Phase 2

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ALK-positive NSCLC

Start: 2019-08-13End: 2022-04-30Target: 135Updated: 2019-10-30

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Non Small Cell Lung Cancer

Start: 2020-08-11End: 2022-10-31Target: 71Updated: 2020-09-11

Phase 3

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ALK-positive NSCLC

Start: 2019-08-13End: 2022-04-30Target: 260Updated: 2019-10-30

Related Papers

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.

2023-08-1420 citations

First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.

2022-08-058 citations

A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-204 citations